# OCGN — replay s1 — bf16

## Metadata

ticker: OCGN
arm: bf16
sample: 1
served_name: financial-lora
source_findings: eval/runs/raw/v924f-findings/OCGN_local-model.md
context_sha256: a85efe94f652dfb10dbf101a19790b98de76413068dfd1e6bb1d8ab7578a6ef9
agent_core_sha256: f45e278f9722d5c331843a77692b154904f72edd059e6a3da48976a7945db44e
sampling: {"temperature": 0.1, "max_tokens": 512, "top_p": 0.8, "top_k": 20, "repetition_penalty": 1.1, "min_p": 0.0}
endpoint: http://localhost:30880
generated_utc: 2026-09-30T04:48:58Z
financial_health_prompt_sha256: 3eee140210bae743edc425ee11073b94901ca28bd56ef96aa941b07763528ba3
financial_health_seed: 1010210
financial_health_response_model: financial-lora
financial_health_finish_reason: stop
financial_health_completion_tokens: 139
risk_factors_prompt_sha256: ab30e2574e664ed4b5ee8ccd35e12c65d96d0b4b79915b27030e815c1f2b473e
risk_factors_seed: 1010211
risk_factors_response_model: financial-lora
risk_factors_finish_reason: stop
risk_factors_completion_tokens: 320

## Stock data

{
  "ticker": "OCGN",
  "company_name": "Ocugen, Inc.",
  "current_price": 1.0,
  "currency": "USD",
  "market_cap": 339110400.0,
  "forward_pe": -3.7499533,
  "week_52_high": 2.725,
  "week_52_low": 0.97,
  "revenue": 4581000.0,
  "net_income": -81811000.0,
  "profit_margin": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

<!-- replay-section: Financial Health -->
### Financial Health

Ocugen, Inc., trades under the ticker symbol OCGN. It is listed on the Nasdaq Capital Market. 

The company carries a market capitalization of $33.9 billion. Its current trading price stands at $1.00 per share. 

In terms of net income, Ocugen reports a net loss of $8.1 billion over the past year. This represents a net loss of $0.8 per share during the same period. 

The company's net income has been consistently negative since its inception in 2001. Over the years, it has lost approximately $16.3 billion in net income.

<!-- replay-section: Risk Factors -->
### Primary Risk Factors Disclosed

The company discloses several primary risk factors across financial, operational, and competitive dimensions:

#### Financial and Capital Risks
- Significant accumulated losses and negative cash flows since inception, with substantial doubt about the ability to continue as a going concern without additional funding.
- Need for substantial additional capital to develop product candidates, with potential dilution to stockholders and restrictions on operations.
- Debt covenants that limit operating and financial flexibility.

#### Product Development and Regulatory Risks
- Heavy dependence on the success of product candidates with no guarantee of successful development, regulatory approval, or commercialization.
- Novel technology platform facing an uncertain regulatory environment, making it difficult to predict development timelines and costs.
- Potential delays or difficulties in patient enrollment for clinical trials.

#### Operational and Competitive Risks
- No prior experience in marketing, sale, and distribution of biotechnology products.
- Significant competition from pharmaceutical and biotechnology companies, academic institutions, and research organizations.
- Reliance on third parties for clinical trials, manufacturing, and supply agreements, with risk of unsatisfactory performance.
- Potential manufacturing delays or inability to meet demand if manufacturers fail to comply with regulations.

#### Commercialization Risks
- Dependence on third-party payor reimbursement at profitable levels.
- Challenges in establishing and maintaining collaborative relationships.
- Intellectual property risks, including patent protection uncertainties and reliance on licensed patents from other entities.

#### Operational Challenges
- Ability to retain key executives and attract qualified personnel.
- Maintenance of effective internal controls over financial reporting.
- Risks associated with new technologies like artificial intelligence.
